• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Echo Therapeutics closes trial, preps for FDA submission in the "near future"

August 24, 2010 By drugdelivery

ECTE logo

Echo Therapeutics Inc. (OTC:ECTE) announced the completion of a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying an application for 510(k) clearance from the Food & Drug Administration is imminent.

The Franklin, Mass.-based company launched the trial in April, in partnership with Ferndale Pharma Group Inc., to test the drug-device combination with Ferndale’s 4 percent topical lidocaine. The needle-free system ablates a thin layer of skin before a drug is applied.

The trial was designed to “evaluate the ability of the Prelude SkinPrep System to ablate the skin prior to application of OTC 4 percent lidocaine cream for local dermal anesthesia.” Echo said the blind comparison study "demonstrated remarkable improvement and an abbreviated onset of action" when its device was used in conjunction with the lidocaine preparation. The pharma firm has a license to develop and sell the Prelude for its 4 percent lidocaine product in North America and the U.K., according to a press release.

Echo posted strong second-quarter results for the three months ended June 30, dramatically increasing its top-line while slashing net losses. Second-quarter net losses were $536,000, or 2 cents per share, on sales of $264,000. That compares with net losses of $6.8 million, or 46 cents per share, on sales of $121,000 during the same period last year.

ECTE shares were trading at $1.15, up nearly 1 percent, in early-morning activity.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Echo Therapeutics Inc.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS